Extension of a predictive substrate model for human cytochrome P4502D6

References

• ALLAN, F. H. and KENNARD, O., 1993,3D search and research using the Cambridge Structural Database. Chemical Design Automation News, 8, 31–37.
   Google Scholar
• ANDREWS, P. R., CRAIK, D. J. and MARTIN, J. L., 1984, Functional group contributions to drug—receptor interactions. Journal of Medicinal Chemistry, 27, 1648–1657.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG, M., FAIRBROTHER, K., IDLE, J. R. and DALY, A. K., 1994, The cytochrome-P450 CYP2D6 allelic variant GYP 2D6J and related polymorphisms in a European population. Pharmaco genetics, 4, 73–81.
   PubMedGoogle Scholar
• BECKE, A. D., 1988, Density- functional exchange- energy approximation with correct asymptotic behavior. Physical Review A, 38, 3098–3100.
   PubMed Web of Science ®Google Scholar
• BLANKSON, E. A., ELus, S. W., L ENNARD, M. S., TUCKER, G. T. and ROGERS, K., 1991, The metabolism of tamoxifen by human liver microsomes is not mediated by cytochrome P4501ID6. Biochemical Pharmacology, 42, S209—S212.
   Google Scholar
• CHEMICAL DESIGN LTD, 1993, ChemX, version January 1993 (Chipping Norton, UK).
   Google Scholar
• CREWE, H. K., ELLis, S. W., L ENNARD, M. S. and TUCKER, G. T., 1996, Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Proceedings of the Sixth Stowe Symposium on Drug Metabolism, 17–20 July, Grantham, UK, P47.
   Google Scholar
• DALY, A. K., BROCKM6 LLER, J., BADLY, F., EICHELBAUM, M., EVANS, W E., GONZALEZ, F. J., HUANG, J. D., IDLE, J. R., I NGELMAN - S UNDBERG, M., I SHIZAKI, T., JACQZ-AIGRAIN, E., MEYER, U. A., NEBERT, D. W S TEEN, V. M., WOLF, C. R. and ZANDER, U. M., 1996, Nomenclature for human GYP 2D6 allelles, Pharmacogenetics, 6, 193–201.
   Google Scholar
• DAYER, P., DESMEULES J., L EEMANN, T. and S TRIBERNI, R., 1988, Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochemical and Biophysical Research Communi-cations, 152, 411–416.
   Google Scholar
• DE GROOT, M. J., BIJLOO, G. J., H ANSEN K. T. and VERMEULEN, N. P. E., 1995, Computer prediction and experimental validation of cytochrome P450-2D6 dependent oxidation of GBR 12909 (1-[2-[bis(4- fluorophenynmet hoxy]ethy1]- 4-(3-phenylpropyl)piperazine). Drug Metabolism and Dis-position, 23, 667–669.
   Google Scholar
• DE GROOT, M. J., B IMOD, G. J., MARTENS, B. J., VAN ACKER, F. A. A. and VERMEULEN, N. P. E., 1997, A refined substrate model for human cytochrome P450 2D6. Chemical Research in Toxicology 10, 41–48.
   PubMedGoogle Scholar
• DE GROOT, M. J., VERMEULEN, N. P. E., K RAMER, J. D., VAN ACKER, F. A. A. and Do-Op DEN K ELDER, G. M., 1996, A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102 and P450 108. Chemical Research in Toxicology, 9, 1079–1091.
   Google Scholar
• DEPARTMENT OF THEORETICAL CHEMISTRY V RUE U NIVERSITEIT AMSTERDAM, 1995, ADF, version 2.0b1.
   Google Scholar
• EICHELBAUM, M. and GROSS, A. S., 1990, The genetic polymorphism of debrisoquine /sparteine metabolism—clinical aspects. Pharmaceutical Therapeutics, 46, 377–394.
   PubMed Web of Science ®Google Scholar
• ELLIS, S. W., ROWLAND, K., ACKLAND, M. J., REKKA, E., SEVIULA, A. P., LENNARD, M. S., WOLF, C. R. and TUCKER, G. T., 1996, Influence of amino acid residue 374 of cytochrome P450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. Biochemical Journal, 316, 647–654.
   PubMed Web of Science ®Google Scholar
• FONNE -PFISTER, R. and MEYER, U. A., 1988, Xenobiotic and endobiotic inhibitors of cytochrome P-450db1 function, the target of the debrisoquine /sparteine type polymorphism. Biochemical Pharmacology, 37, 3829–3835.
   PubMedGoogle Scholar
• FONSECA GUERRA, C., VISSER, O., S NIJDERS, J. G., TE VELDE, G. and BAERENDS, E. J., 1995, Parallelisation of the Amsterdam Density Functional program. In Methods and Techniques in Computational Chemistry. METECC -95, edited by E. Clementi and C. Corongiu (Cagliari), pp. 305–395.
   Google Scholar
• GOEPTAR, A. R., S CHEERENS, H. and VERMEULEN, N. P. E., 1995, Oxygen and xenobiotic reductase activities of cytochrome P450. Critical Reviews in Toxicology, 25, 25–65.
   PubMed Web of Science ®Google Scholar
• HASEMANN, C. A., RAVICHANDRAN, K. G., PETERSON, J. A. and DEISENHOFER, J., 1994, Crystal structure and refinement of cytochrome P450t at 2.3 A resolution. Journal of Molecular Biology, 236, 1169–1185.
   PubMed Web of Science ®Google Scholar
• ISLAM, S. A., WOLF, C. R., L ENNARD, M. S. and S TERNBERG, M. J. E., 1991, A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcino genesis, 12, 2211–2219.
   PubMed Web of Science ®Google Scholar
• JARURATANASIRIKU L, S. and H ORTIWAKUL, R., 1994, The inhibitory effect of amiodarone and desethylamiodar one on dextromethorph a n O-demethylation in human and rat liver microsom es. Journal of Pharmaceutical Pharmacology, 46, 933–935.
   PubMedGoogle Scholar
• KORZEKWA, K. R. and Jos, J. P., 1993, Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics, 3, 1–18.
   PubMedGoogle Scholar
• KOYMANS, L. M. H., D ONNE -OP DEN K ELDER, G. M., TE K OPPELE, J. M. and VERMEULEN, N. P. E., 1993a, Cytochromes P450 : their active site structure and mechanism of oxidation. Drug Metabolism Reviews, 25, 325–387.
   Google Scholar
• KOYMANS, L. M. H., VERMEULEN, N. P. E., BAARSLAG, A. and DONNE -Op DEN KELDER, G. M., 1993b, A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. Journal of Computer-Aided Molecular Design, 7, 281–289.
   Google Scholar
• KOYMANS, L. M. H., VERMEULEN, N. P. E., VAN ACKER, S. A. B. E., TE K OPPELE, J. M., HEYKANTS J. J. P., L AVRILSEN, K., M EULDERMANS W. and D °NNE.- OP DEN K ELDER, G. M., 1992, A predictive model for substrates of cytochrome P-450-debrisoquine (2D6). Chemical Research in Toxicology, 5,211–219.
   Google Scholar
• KROEMER, H. K. and EICHELBAU M., 1995, 'It's the genes, stupid'. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sciences, 56, 2285–2298.
   PubMed Web of Science ®Google Scholar
• LENNARD, M. S., T UCKER, G. T., SILAS, J. H. and WOODS, H. F., 1986, Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propanolol and atenolol. Xenobiotica, 16, 435–447.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F. V., 1995, Three- dimensional models of human and other mammalian microsomal P450s constructed from an alignment with CYP102 (P450bm3). Xenobiotica, 25, 333–366.
   PubMed Web of Science ®Google Scholar
• LI, H. and Pouws, T. L., 1995, Modeling protein—substrate interactions in the heme domain of cytochrome P450,3„„.3. Acta Crystallographica Section D—Biological Crystallography, 51, 21–32.
   PubMed Web of Science ®Google Scholar
• MANI, C., GELBOIN, H. V., PARK, S S., PEARCE, R., PARKINSON, A. and KUPFER, D., 1993, Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metabolism and Disposition, 21, 645–656.
   PubMed Web of Science ®Google Scholar
• MANI, C. and K UPFER, D., 1991, Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of Rayon-containing monoxygenases in tamoxifen activation. Cancer Research, 51, 6052–6058.
   PubMed Web of Science ®Google Scholar
• MAUTZ, D. S., NELSON, W L. and S HEN, D. D. 1995, Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsom es containing cDNA- expressed human P4502D6. Drug Metabolism and Disposition, 23, 513–517.
   PubMed Web of Science ®Google Scholar
• MEYER, U. A., GUT, J., KRONBACH, T., SKODA, C., M EIER, U. T., CATIN, T. and D AYER, P., 1986, The molecular mechanism of two common polymorphisms of drug oxidation. Evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica, 16, 449–464.
   PubMed Web of Science ®Google Scholar
• MEYER, U. A., S KODA, R. C. and ZANGER, U. M., 1990, The genetic polymorphism of debrisoquine sparteine metabolism- molecular mechanisms. Pharmaceutical Therapeutics, 46, 297–308.
   PubMed Web of Science ®Google Scholar
• MIKUS, G., BOCHNER, F., EICHELBAUM, M., HORAK, P., SOMOGYI, A. A. and SPECTOR, S., 1994, Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine /sparteine) polymorphism. Journal of Pharmacology and Experimental Therapeutics, 268, 546–551.
   PubMed Web of Science ®Google Scholar
• MIKUS, G., S OMOGYI, A. A., B OCHNER, F. and EICHELBAU M., 1991, Codeine O-demethylation : rat strain differences and the effects of inhibitors. Biochemical Pharmacology, 41, 757–762.
   PubMed Web of Science ®Google Scholar
• MODI, S., PAINE, M. J., SUTCLIFFE, M. J., L IAN, L. Y., PRIMROSE, W U., WOLF, C. R. and ROBERTS, G. C. K., 1996, A model for human cytochrome P 2D6 based on homology modeling and NMR studies of substrate binding. Biochemistry, 35, 4540–4550.
   PubMed Web of Science ®Google Scholar
• NELSON, D. R., KOYMANS, L., KAMATAKI, T., S TEGEMAN, J. J., FEYEREISEN, R., W AXMAN D. J., W ATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS I. C. and N EBERT, D. W., 1996, P450 superfamily : update on new sequences, gene mapping, accession numbers and nomenclature. Pharmqcogenetics, 6, 1–42.
   Google Scholar
• PANSERAT, S., M URA, C., GERARD, N., VINCENT -V IRY, M., GALTEAU M. M., JACQZ-AIGRAIN, E. and K RISHNAMOORTHY, R., 1994, DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6) : evidence for two major allozymes in extensive metabolisers. Human Genetics, 94, 401–406.
   Google Scholar
• PARR, R. G. and YANG, W., 1989, Density-Functional Theory of Atoms and Molecules (New York: Oxford University Press).
   Google Scholar
• PERDEW, J. P., 1986, Density- functional approximation for the correlation energy of the inhomogeneous electron gas. Physical Review B, 33, 8822–8824.
   PubMed Web of Science ®Google Scholar
• PIERCE, D. M., SMITH, S. E. and FRANKLIN, R. A., 1987, The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. European Journal of Clinical Pharmacology, 33, 59–65.
   PubMed Web of Science ®Google Scholar
• POULOS, T. L., FINZEL, B. C., GUNSALUS I. C., WAGNER, G. C. and KRAUT, J., 1985, The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450. Journal of Biological Chemistry, 260, 16122–16130.
   Google Scholar
• RAVICHANDRAN, K. G., BODDUPALLI, S. S., H ASEMANN C. A., PETERSON, J. A. and DEISENHOFER, J., 1993, Crystal structure of hemoprotein domain of P450BM- 3, a prototype for microsomal P450s. Science, 261, 731–736.
   Google Scholar
• SCREATON, G. R., CAIRNS, H. S., S ARNER, M., SINGER, M., THRASHER, A. and COHEN, S. L., 1992, Hyperpyrexia and rhabdomyolysis after M DMA (` ecstasy ') abuse. Lancet, 339, 677–678.
   PubMed Web of Science ®Google Scholar
• STROBL, G. R., VON KREUDENER, S., S TO CKIGT, J., GUENGERICH, F. P. and W OLFF, T., 1993, Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modelling and inhibition studies. Journal of Medicinal Chemistry, 36, 1136–1145.
   PubMed Web of Science ®Google Scholar
• STYLES, J. A., DAVIES, A., L EVI, C. K., MATTEIS, F. D., STANLEY, L. A., WHITE, I. N. H., YUAN, Z.-X. and SMITH, L. L., 1994, Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcino genesis, 15, 5–9.
   Google Scholar
• TUCKER, G. T., LENNARD, M. S., ELLIS, S. W W OODS, H. F., CHO, A. K., L IN, L. Y., H IRATSUKA, A., S MITZ, D. A. and CHu, T. Y. Y., 1994, The demethylation of methylenedioxym ethamphetamine (` Ecstasy ') by Debrisoquine hydrolase (CYP2D6). Biochemical Pharmacology, 47, 1151–1156.
   PubMed Web of Science ®Google Scholar
• VOSKO, S. H., WILK, L. and N USAIR, M., 1980, Accurate spin-dependent electron liquid correlation energies for local spin density calculations: a critical analysis. Canadian Journal of Physics, 58, 1200–1211.
   Web of Science ®Google Scholar
• WHITE, I. N. H., DE M ATTEIS, F., GIBBS, A. H., Lim, C. K., WOLF, C. R., HENDERSON, C. and SMITH, L. L., 1995, Species differences in the covalent binding of ['4C]tamoxifen to liver microsom es and the forms of cytochrome P450 involved. Biochemical Pharmacology, 49, 1035–1042.
   Google Scholar
• WILLIAMS, D. H., Cox, J. P. L., DOIG, A. J., GARDNER, M., GERHARD, U., K AYE, P. T., L AL, A. R., IshcHoLLs, I. A., SALTER, C. J. and MITCHELL, R. C., 1991, Toward the semiquantitative estimation of binding constants. Guides for peptide—peptide binding in aqueous solution. Journal of the American Chemical Society, 113, 7020–7030.
   Google Scholar
• WISEMAN, H. and LEWIS, D. F. V., 1996, The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme—substrat e interactions : potential importance to its proposed anti-carcinogen/carcinogen actions. Carcino genesis, 17, 1357–1360.
   PubMed Web of Science ®Google Scholar
• WOLFF, T., DISTLERATH, L. M., WORTHINGTON, M. T., GROOPMAN, J. D., H AMMONS, G. J., KADLUBAR, F. F., PROUGH, R. A., M ARTIN M V. and GUENGERICH, F. P., 1985, Substrate specificity of human liver cytochrome P-450 debrisoquine hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Research, 45, 2116–2122.
   Google Scholar
• YUE, Q. Y. and S AWE, S., 1992, Interindividual and interethnic differences in codeine metabolism. In Pharmacogenetics of Drug Metabolism, edited by W. Kalow (New York: Pergamon), pp. 721–727.
   Google Scholar